The impact of complete chemotherapy stop on the overall survival of patients with advanced colorectal cancer in first-line setting: A meta-analysis of randomized trials

Imagem de Miniatura
Arquivos
art_PEREIRA_The_impact_of_complete_chemotherapy_stop_on_the_2015.PDF (730.8 KB)
Citações na Scopus
18
Tipo de produção
article
Data de publicação
2015
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
TAYLOR & FRANCIS LTD
Autores
SASSE, Andre Deeke
Citação
ACTA ONCOLOGICA, v.54, n.10, p.1737-1746, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background. The impact of the duration of chemotherapy on the overall survival of patients with metastatic colorectal cancer (mCRC) is controversial and studies have failed to define a clear standard.Methods. We searched medical literature databases and oncology conferences proceedings for randomized controlled trials (RCT) that compared the overall survival of mCRC patients who received continuous first-line chemotherapy until disease progression versus those who were offered complete treatment stop after a fixed number of cycles. Studies including targeted agents were also included. A meta-analysis of reported hazard ratios (HRs) for survival was performed.Results. We retrieved 240 trials, of which six were eligible and five were included in the pooled analysis of overall survival (N = 3061). The overall survival between continuously delivered chemotherapy and complete stop was not statistically different (HR = 0.93, 95% CI 0.85-1.02; p = 0.12; I-2 = 5%). The results are similar when we analyzed separately the trials performing randomization before versus after induction therapy. The median chemotherapy free interval in the complete stop group was 3.9 months (3.6-4.3 months). Chemotherapy administered until progression was associated with more adverse effects and impaired quality of life.Conclusion. Compared with first-line continuous chemotherapy administered until disease progression, complete treatment stop did not have a detrimental impact on the overall survival of patients with mCRC. Identification of predictive biomarkers could help clinicians to select the patients who would benefit from continuous cancer-directed therapies.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/12679
Referências
  1. AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
  2. Alexopoulos CG, 2006, J CLIN ONCOL, V24, p166S
  3. Tveit KM, 2012, J CLIN ONCOL, V30, P1755, DOI 10.1200/JCO.2011.38.0915
  4. de Gramont A, 2000, J CLIN ONCOL, V18, P2938
  5. Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091
  6. Rashid MH, 2004, ONCOLOGIST, V9, P295, DOI 10.1634/theoncologist.9-3-295
  7. Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113
  8. Maughan TS, 2003, LANCET, V361, P457, DOI 10.1016/S0140-6736(03)12461-0
  9. Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
  10. Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
  11. Beex L, 2006, EUR J CANCER, V42, P3178, DOI 10.1016/j.ejca.2006.08.020
  12. Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1
  13. Lima JPDN, 2009, EUR J CANCER, V45, P601, DOI 10.1016/j.ejca.2008.11.006
  14. Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
  15. Labianca R, 2011, ANN ONCOL, V22, P1236, DOI 10.1093/annonc/mdq580
  16. Kohne CH, 2002, ANN ONCOL, V13, P308, DOI 10.1093/annonc/mdf034
  17. STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K
  18. Chibaudel B, 2009, J CLIN ONCOL, V27, P5727, DOI 10.1200/JCO.2009.23.4344
  19. Gennari A, 2006, J CLIN ONCOL, V24, P3912, DOI 10.1200/JCO.2006.06.1812
  20. Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930
  21. Tournigand C, 2006, J CLIN ONCOL, V24, P394, DOI 10.1200/JCO.2005.03.0106
  22. Koopman M, 2007, LANCET, V370, P135, DOI 10.1016/S0140-6736(07)61086-1
  23. Berry SR, 2015, ANN ONCOL, V26, P477, DOI 10.1093/annonc/mdu272
  24. Adams RA, 2011, LANCET ONCOL, V12, P642, DOI 10.1016/S1470-2045(11)70102-4
  25. Seymour MT, 2007, LANCET, V370, P143, DOI 10.1016/S0140-6736(07)61087-3
  26. de Gramont A, 2007, J CLIN ONCOL, V25, P3224, DOI 10.1200/JCO.2006.10.4380
  27. Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046
  28. Kang GH, 2011, ARCH PATHOL LAB MED, V135, P698, DOI 10.1043/2010-0523-RA.1
  29. Soon YY, 2009, J CLIN ONCOL, V27, P3277, DOI 10.1200/JCO.2008.19.4522
  30. Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
  31. Goldberg RM, 2006, J CLIN ONCOL, V24, P3347, DOI 10.1200/JCO.2006.06.1317
  32. Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175
  33. Colucci G, 2005, J CLIN ONCOL, V23, P4866, DOI 10.1200/JCO.2005.07.113
  34. Cassidy J, 2008, J CLIN ONCOL, V26, P2006, DOI 10.1200/JCO.2007.14.9898
  35. De Gramont A, 2013, EUROPEAN CANC C S, V49
  36. Hegewisch-Becker S, 2014, ANN ONCOL S4, V25
  37. Koopman M, 2014, ASCO M ABSTRACTS S, V32, P3504
  38. Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
  39. Rossi A, 2014, LANCET ONCOL, V15, P1254, DOI 10.1016/S1470-2045(14)70402-4
  40. Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254
  41. Tabernero J, 2010, ASCO M ABSTRACTS S, V28, P3501
  42. Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
  43. Tournigand C, 2012, J CLIN ONCOL, V30, p3500a
  44. ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03